← All trials
NCT05119426
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Nov 15, 2021
- Last posted
- Nov 15, 2021
- Enrollment
- 48000
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International Vaccine InstituteLead sponsor
- University of CambridgeOverall official - principal investigator
- University of CambridgeCollaborator
- Institute of Tropical Medicine, BelgiumCollaborator
- Government of CongoCollaborator
- Government of CongoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.